Research Investigating Drug Effects-2 (RiDE-2)

Launched by UNIVERSITY OF ILLINOIS AT CHICAGO · Dec 26, 2024

Keywords

ClinConnect Summary

The RiDE-2 clinical trial is exploring how different recreational drugs, like cannabis, affect people's moods, behaviors, and brain activity. Researchers want to understand why some individuals may react differently to the same drug, which can help in treating substance use disorders. The study is looking for participants aged 18 to 21 who have used cannabis at least ten times in their life, with some use in the past three months. To be eligible, participants should be in good health and have no serious mental illnesses or significant medical conditions.

If selected for the trial, participants will undergo assessments to learn more about their experiences with cannabis. It’s important to note that individuals who are pregnant, have certain medical conditions, or are taking specific medications may not qualify for the study. Participants will also be screened to ensure their safety throughout the trial. This research could provide valuable insights into how cannabis and similar substances affect the brain, ultimately helping those who struggle with substance use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age 18-21 at eligibility visit
• • body mass index of 18.5-30
• • report using cannabis ≥10 times in their life and ≥1 time in the past 3 months, but \<7 days a week (daily)
• • medically and neurologically healthy
• • score of ≥0.25 on the Personality Inventory for DSM-5 (PID-5) Anhedonia subscale
• Exclusion Criteria:
• • positive urine drug screen (UDS; except for THC) and/or positive saliva THC test
• • contraindication for fMRI BOLD study (e.g., metal implants)
• • severe mental illness (e.g., psychosis, mania, lifetime moderate-to-severe SUD (including moderate-to-severe CUD))
• • heavy nicotine use in the past month (\>20 cigarettes per week or electronic nicotine delivery system (ENDS) use equivalent
• • night shift work
• • females who are currently pregnant confirmed by urine pregnancy test, are planning pregnancy, or are lactating
• • unwilling/unable to sign informed consent document
• • current or past allergic or adverse reaction or known sensitivity to cannabinoid-like substances (Dronabinol/Marijuana/Cannabis/THC, cannabinoid oil, sesame oil, gelatin, glycerin, and titanium dioxide)
• • physical or neurological diagnoses (e.g., cancer, diabetes, seizure disorder, Parkinson's, Multiple Sclerosis, loss of consciousness \>10 min., etc.) that in the opinion of the Study Physician and Investigators could increase safety risks or influence the findings
• • currently taking any medication that could interact with a single dose of Δ9-THC